Migration of dendritic cells to the lymph nodes and its enhancement to drive anti-tumor responses

Critical Reviews in Oncology/Hematology

Volumn 107, Issue , 2016, Pages 100-110

  Seyfizadeh, Narges ^a   Muthuswamy, Ravikumar ^b   Mitchell, Duane A ^c   Nierkens, Stefan ^d   Seyfizadeh, Nayer ^e,f  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cancer vaccine; Dendritic cell; Immunotherapy; Lymph node homing; Migration to the lymph node

Indexed keywords

ALPHA INTERFERON; CANCER VACCINE; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR4; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; PROSTAGLANDIN E2; RHO KINASE; SECONDARY LYMPHOID TISSUE CHEMOKINE; STROMAL CELL DERIVED FACTOR 1; TUMOR NECROSIS FACTOR;

CANCER IMMUNOTHERAPY; CELL MATURATION; CELL MIGRATION; CELL TRACKING; CELLULAR STRESS RESPONSE; CHEMOTAXIS; COMPUTER ASSISTED TOMOGRAPHY; DENDRITIC CELL; ENDOTHELIUM CELL; GENE EXPRESSION; INFLAMMATION; LYMPH NODE; LYMPHATIC ENDOTHELIAL CELL; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ANIMAL; CELL MOTION; CYTOLOGY; HUMAN; IMMUNOLOGY; NEOPLASM; T LYMPHOCYTE;

ANIMALS; CELL MOVEMENT; DENDRITIC CELLS; HUMANS; INFLAMMATION; LYMPH NODES; NEOPLASMS; T-LYMPHOCYTES;

EID: 85011771673     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2016.09.002     Document Type: Review

References (116)

1. Aarntzen, E.H., Srinivas, M., Schreibelt, G., Heerschap, A., Punt, C.J., Figdor, C.G., et al. Reducing cell number improves the homing of dendritic cells to lymph nodes upon intradermal vaccination. Oncoimmunology, 2, 2013.
2. Aarntzen, E.H., Srinivas, M., Bonetto, F., Cruz, L.J., Verdijk, P., Schreibelt, G., et al. Targeting of 111In-labeled dendritic cell human vaccines improved by reducing number of cells. Clin. Cancer Res. 19 (2013), 1525–1533.
3. Acton, S.E., Astarita, J.L., Malhotra, D., Lukacs-Kornek, V., Franz, B., Hess, P.R., et al. Podoplanin-rich stromal networks induce dendritic cell motility via activation of the C-type lectin receptor CLEC-2. Immunity 37 (2012), 276–289.
4. Adema, G.J., de Vries, I.J.M., Punt, C.J., Figdor, C.G., Migration of dendritic cell based cancer vaccines: in vivo veritas?. Curr. Opin. Immunol. 17 (2005), 170–174.
5. Alamino, V.A., Mascanfroni, I.D., Montesinos, M.M., Gigena, N., Donadio, A.C., Blidner, A.G., et al. Antitumor responses stimulated by dendritic cells are improved by triiodothyronine binding to the thyroid hormone receptor β. Cancer Res. 75 (2015), 1265–1274.
6. Alaniz, L., Rizzo, M., Garcia, M.G., Piccioni, F., Aquino, J.B., Malvicini, M., et al. Low molecular weight hyaluronan preconditioning of tumor-pulsed dendritic cells increases their migratory ability and induces immunity against murine colorectal carcinoma. Cancer Immunol. Immunother. 60 (2011), 1383–1395.
7. Ashour, A.E., Turnquist, H.R., Singh, R.K., Talmadge, J.E., Solheim, J.C., CCL21-induced immune cell infiltration. Int. Immunopharmacol. 7 (2007), 272–276.
8. Astarita, J.L., The role of the podoplanin-CLEC-2 pathway in stromal cell regulation of dendritic cell motility and lymph node architecture. Diss, 2014.
9. Awasthi, S., Awasthi, V., Magee, D.M., Coalson, J.J., Efficacy of antigen 2/proline-rich antigen cDNA-transfected dendritic cells in immunization of mice against Coccidioides posadasii. J. Immunol. 175 (2005), 3900–3906.
10. Ban, E., Dupré, L., Hermann, E., Rohn, W., Vendeville, C., Quatannens, B., et al. CpG motifs induce Langerhans cell migration in vivo. Int. Immunol. 12 (2000), 737–745.
11. Bao, X., Moseman, E.A., Saito, H., Petryanik, B., Thiriot, A., Hatakeyama, S., et al. Endothelial heparan sulfate controls chemokine presentation in recruitment of lymphocytes and dendritic cells to lymph nodes. Immunity 33 (2010), 817–829.
12. Baumjohann, D., Lutz, M.B., Non-invasive imaging of dendritic cell migration in vivo. Immunobiology 211 (2006), 587–597.
13. Bedrosian, I., Mick, R., Xu, S., Nisenbaum, H., Faries, M., Zhang, P., et al. Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. J. Clin. Oncol. 21 (2003), 3826–3835.
14. Benhamron, S., Nechushtan, H., Verbovetski, I., Krispin, A., Abboud-Jarrous, G., Zcharia, E., et al. Translocation of active heparanase to cell surface regulates degradation of extracellular matrix heparan sulfate upon transmigration of mature monocyte-derived dendritic cells. J. Immunol. 176 (2006), 6417–6424.
15. Bianchi, R., Teijeira, A., Proulx, S.T., Christiansen, A.J., Seidel, C.D., Rülicke, T., et al. A Transgenic Pro-Cre-tdTomato Reporter Mouse for Lymphatic Vessel Research. PloS One, 10.4, 2015, e0122976.
16. Braun, A., Worbs, T., Moschovakis, G.L., Halle, S., Hoffmann, K., Bölter, J., et al. Afferent lymph-derived T cells and DCs use different chemokine receptor CCR7-dependent routes for entry into the lymph node and intranodal migration. Nat. Immunol. 12 (2011), 879–887.
17. Carragher, D.M., Rangel-Moreno, J., Randall, T.D., Ectopic lymphoid tissues and local immunity. Semin. Immunol. 20 (2008), 26–42.
18. Carreno, B.M., Magrini, V., Becker-Hapak, M., Kaabinejadian, S., Hundal, J., Petti, A.A., et al. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 348 (2015), 803–808.
19. Chen, S.C., Vassileva, G., Kinsley, D., Holzmann, S., Manfra, D., Wiekowski, M.T., et al. Ectopic expression of the murine chemokines CCL21a and CCL21b induces the formation of lymph node-like structures in pancreas, but not skin, of transgenic mice. J. Immunol. 168 (2002), 1001–1008.
20. Chen, X., Zeng, Q., Wu, M.X., Improved efficacy of dendritic cell–based immunotherapy by cutaneous laser illumination. Clin. Cancer Res. 18 (2012), 2240–2249.
21. Chen, Y.-Z., Ruan, G.-X., Yao, X.-L., Li, L.-M., Hu, Y., Tabata, Y., et al. Co-transfection gene delivery of dendritic cells induced effective lymph node targeting and anti-tumor vaccination. Pharm. Res. 30 (2013), 1502–1512.
22. Clatworthy, M.R., Aronin, C.E.P., Mathews, R.J., Morgan, N.Y., Smith, K.G., Germain, R.N., Immune complexes stimulate CCR7-dependent dendritic cell migration to lymph nodes. Nat. Med. 20 (2014), 1458–1463.
23. Dekaban, G.A., Hamilton, A.M., Fink, C.A., Au, B., de Chickera, S.N., Ribot, E.J., et al. Tracking and evaluation of dendritic cell migration by cellular magnetic resonance imaging. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 5 (2013), 469–483.
24. Di Caro, G., Bergomas, F., Grizzi, F., Doni, A., Bianchi, P., Malesci, A., et al. Occurrence of tertiary lymphoid tissue is associated with T-cell infiltration and predicts better prognosis in early-stage colorectal cancers. Clin. Cancer Res. 20 (2014), 2147–2158.
25. Dieu-Nosjean, M.C., Antoine, M., Danel, C., Heudes, D., Wislez, M., Poulot, V., et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J. Clin. Oncol. 26 (2008), 4410–4417.
26. Drayton, D.L., Ying, X., Lee, J., Lesslauer, W., Ruddle, N.H., Ectopic LT alpha beta directs lymphoid organ neogenesis with concomitant expression of peripheral node addressin and a HEV-restricted sulfotransferase. J. Exp. Med. 197 (2003), 1153–1163.
27. Dudek, A., Martin, S., GARG, A., Agostinis, P., Immature semi-mature, and fully mature dendritic cells: toward a DC-cancer cells interface that augments anticancer immunity. Front. Immunol., 11, 2013, 438.
28. Fehres, C.M., Bruijns, S., Beelen, A.J., Kalay, H., Ambrosini, M., Hooijberg, E., et al. Topical rather than intradermal application of the TLR7 ligand imiquimod leads to human dermal dendritic cell maturation and CD8+ T‐cell cross‐priming. Eur. J. Immunol. 44 (2014), 2415–2424.
29. Fong, L., Brockstedt, D., Benike, C., Wu, L., Engleman, E.G., Dendritic cells injected via different routes induce immunity in cancer patients. J. Immunol. 166 (2001), 4254–4259.
30. Frauke, S., Felix, L., Christiane, G., Reinhard, H., Beate, W., Iris, B., et al. ITOC2-022. Vaccination with next-generation dendritic cells for AML postremission therapy induces antigen-specific T cell responses. Eur. J. Cancer, 51, 2015, S8.
31. González, F.E., Ortiz, C., Reyes, M., Dutzan, N., Patel, V., Pereda, C., et al. Melanoma cell lysate induces CCR7 expression and in vivo migration to draining lymph nodes of therapeutic human dendritic cells. Immunology 142 (2014), 396–405.
32. Griffiths, C., Dearman, R., Cumberbatch, M., Kimber, I., Cytokines and Langerhans cell mobilisation in mouse and man. Cytokine 32 (2005), 67–70.
33. Grivennikov, S.I., Greten, F.R., Karin, M., Immunity, inflammation, and cancer. Cell 140 (2010), 883–899.
34. Gunn, M.D., Kyuwa, S., Tam, C., Kakiuchi, T., Matsuzawa, A., Williams, L.T., et al. Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. J. Exp. Med. 189 (1999), 451–460.
35. Hansen, M., Hjortø, G.M., Donia, M., Met, Ö., Larsen, N.B., Andersen, M.H., et al. Comparison of clinical grade type 1 polarized and standard matured dendritic cells for cancer immunotherapy. Vaccine 31 (2013), 639–646.
36. Harada, Y., Tanaka, Y., Terasawa, M., Pieczyk, M., Habiro, K., Katakai, T., et al. DOCK8 is a Cdc42 activator critical for interstitial dendritic cell migration during immune responses. Blood 119 (2012), 4451–4461.
37. Hargadon, K.M., Tumor-altered dendritic cell function: implications for anti-tumor immunity. Front. Immunol., 4, 2013, 3389.
38. Harizi, H., Gualde, N., The impact of eicosanoids on the crosstalk between innate and adaptive immunity: the key roles of dendritic cells. Tissue Antigens 65 (2005), 507–514.
39. Horiguchi, S., Matsuoka, T., Okamoto, Y., Sakurai, D., Kobayashi, K., Chazono, H., et al. Migration of tumor antigen-pulsed dendritic cells after mucosal administration in the human upper respiratory tract. J. Clin. Immunol. 27 (2007), 598–604.
40. Hwang, S.T., Homeward bound: how do skin dendritic cells find their way into the lymph system?. J. Invest. Dermatol. 132 (2012), 1070–1073.
41. Imai, K., Minamiya, Y., Koyota, S., Ito, M., Saito, H., Sato, Y., et al. Inhibition of dendritic cell migration by transforming growth factor-beta1 increases tumor-draining lymph node metastasis. J. Exp. Clin. Cancer Res., 31, 2012, 3.
42. Ishida, T., Oyama, T., Carbone, D.P., Gabrilovich, D.I., Defective function of Langerhans cells in tumor-bearing animals is the result of defective maturation from hemopoietic progenitors. J. Immunol. 161 (1998), 4842–4851.
43. Johnson, L.A., Jackson, D.G., Inflammation-induced secretion of CCL21 in lymphatic endothelium is a key regulator of integrin-mediated dendritic cell transmigration. Int. Immunol. 22 (2010), 839–849.
44. Johnson, L.A., Jackson, D.G., The chemokine CX3CL1 promotes trafficking of dendritic cells through inflamed lymphatics. J. Cell Sci. 126 (2013), 5259–5270.
45. Johnson, L.A., Clasper, S., Holt, A.P., Lalor, P.F., Baban, D., Jackson, D.G., An inflammation-induced mechanism for leukocyte transmigration across lymphatic vessel endothelium. J. Exp. Med. 203 (2006), 2763–2777.
46. Kabashima, K., Shiraishi, N., Sugita, K., Mori, T., Onoue, A., Kobayashi, M., et al. CXCL12-CXCR4 engagement is required for migration of cutaneous dendritic cells. Am. J. Pathol. 171 (2007), 1249–1257.
47. Kalinski, P., Nakamura, Y., Watchmaker, P., Giermasz, A., Muthuswamy, R., Mailliard, R.B., Helper roles of NK and CD8+ T cells in the induction of tumor immunity. Polarized dendritic cells as cancer vaccines. Immunol. Res. 36 (2006), 137–146.
48. Kim, J.H., Kang, T.H., Noh, K.H., Kim, S.-H., Lee, Y.-H., Kim, K.W., et al. Enhancement of DC vaccine potency by activating the PI3K/AKT pathway with a small interfering RNA targeting PTEN. Immunol. Lett. 134 (2010), 47–54.
49. Kim, J.Y., Kim, Y.J., Kim, J.S., Ryu, H.S., Lee, H.K., Kang, J.S., et al. Adjuvant effect of a natural TLR4 ligand on dendritic cell-based cancer immunotherapy. Cancer Lett. 313 (2011), 226–234.
50. Kircher, M.F., Gambhir, S.S., Grimm, J., Noninvasive cell-tracking methods. Nat. Rev. Clin. Oncol. 8 (2011), 677–688.
51. Kreiter, S., Vormehr, M., van de Roemer, N., Diken, M., Lower, M., Diekmann, J., et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 520 (2015), 692–696.
52. Lämmermann, T., Bader, B.L., Monkley, S.J., Worbs, T., Wedlich-Söldner, R., Hirsch, K., et al. Rapid leukocyte migration by integrin-independent flowing and squeezing. Nature 453 (2008), 51–55.
53. Lamana, A., Martin, P., de la Fuente, H., Martinez-Munoz, L., Cruz-Adalia, A., Ramirez-Huesca, M., et al. CD69 modulates sphingosine-1-phosphate-induced migration of skin dendritic cells. J. Invest. Dermatol. 131 (2011), 1503–1512.
54. Lesterhuis, W.J., de Vries, I.J.M., Schreibelt, G., Lambeck, A.J., Aarntzen, E.H., Jacobs, J.F., et al. Route of administration modulates the induction of dendritic cell vaccine–induced antigen-specific T cells in advanced melanoma patients. Clin. Cancer Res. 17 (2011), 5725–5735.
55. Luther, S.A., Bidgol, A., Hargreaves, D.C., Schmidt, A., Xu, Y., Paniyadi, J., et al. Differing activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis. J. Immunol. 169 (2002), 424–433.
56. Ma, J., Wang, J.-H., Guo, Y.-J., Sy, M.-S., Bigby, M., In vivo treatment with anti-ICAM-1 and anti-LFA-1 antibodies inhibits contact sensitization-induced migration of epidermal Langerhans cells to regional lymph nodes. Cell. Immunol. 158 (1994), 389–399.
57. Maddaluno, L., Verbrugge, S.E., Martinoli, C., Matteoli, G., Chiavelli, A., Zeng, Y., et al. The adhesion molecule L1 regulates transendothelial migration and trafficking of dendritic cells. J. Exp. Med. 206 (2009), 623–635.
58. Mailliard, R.B., Alber, S.M., Shen, H., Watkins, S.C., Kirkwood, J.M., Herberman, R.B., et al. IL-18-induced CD83 + CCR7+ NK helper cells. J. Exp. Med. 202 (2005), 941–953.
59. Martín-Fontecha, A., Sebastiani, S., Höpken, U.E., Uguccioni, M., Lipp, M., Lanzavecchia, A., et al. Regulation of dendritic cell migration to the draining lymph node impact on T lymphocyte traffic and priming. J. Exp. Med. 198 (2003), 615–621.
60. McDonnell, A.M., Currie, A.J., Brown, M., Kania, K., Wylie, B., Cleaver, A., et al. Tumor cells, rather than dendritic cells, deliver antigen to the lymph node for cross-presentation. Oncoimmunology 1 (2012), 840–846.
61. Meier, D., Bornmann, C., Chappaz, S., Schmutz, S., Otten, L.A., Ceredig, R., et al. Ectopic lymphoid-organ development occurs through interleukin 7-mediated enhanced survival of lymphoid-tissue-inducer cells. Immunity 26 (2007), 643–654.
62. Mellman, I., Nussenzweig, M., Steinman, Ralph M., (1943–2011) 2011. Science 334, 466.
63. Mitchell, D.A., Batich, K.A., Gunn, M.D., Huang, M.-N., Sanchez-Perez, L., Nair, S.K., et al. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature 519 (2015), 366–369.
64. Mule, J.J., Dendritic cell-based vaccines for pancreatic cancer and melanoma. Ann. N. Y. Acad. Sci. 1174 (2009), 33–40.
65. Muller, W., Greene, T., Liao, F., Transendothelial migration and interstitial migration of monocytes are mediated by separate domains of monocyte CD31. Leukocyte Typing VI Proceedings of the VIth International Leukocyte Differentiation Antigen Workshop Kobe, Japan, 1996, Garland Publishers, London, 370–372.
66. Muthuswamy, R., Urban, J., Lee, J.J., Reinhart, T.A., Bartlett, D., Kalinski, P., Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation. Cancer Res. 68 (2008), 5972–5978.
67. Muthuswamy, R., Mueller-Berghaus, J., Haberkorn, U., Reinhart, T.A., Schadendorf, D., Kalinski, P., PGE2 transiently enhances DC expression of CCR7 but inhibits the ability of DCs to produce CCL19 and attract naive T cells. Blood, 116, 2010, 1454.
68. Nair, S., McLaughlin, C., Weizer, A., Su, Z., Boczkowski, D., Dannull, J., et al. Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J. Immunol. 171 (2003), 6275–6282.
69. Nestle, F.O., Farkas, A., Conrad, C., Dendritic-cell-based therapeutic vaccination against cancer. Curr. Opin. Immunol. 17 (2005), 163–169.
70. Nitschké, M., Aebischer, D., Abadier, M., Haener, S., Lucic, M., Vigl, B., et al. Differential requirement for ROCK in dendritic cell migration within lymphatic capillaries in steady-state and inflammation. Blood 120 (2012), 2249–2258.
71. Obermajer, N., Muthuswamy, R., Odunsi, K., Edwards, R.P., Kalinski, P., PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res. 71 (2011), 7463–7470.
72. Obermajer, N., Muthuswamy, R., Lesnock, J., Edwards, R.P., Kalinski, P., Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood 118 (2011), 5498–5505.
73. Oliver, G., Detmar, M., The rediscovery of the lymphatic system: old and new insights into the development and biological function of the lymphatic vasculature. Genes Dev. 16 (2002), 773–783.
74. Pimenta, E.M., Barnes, B.J., Role of tertiary lymphoid structures (TLS) in anti-tumor immunity: potential tumor-induced cytokines/chemokines that regulate TLS formation in epithelial-derived cancers. Cancers (Basel) 6 (2014), 969–997.
75. Pinner, S., Turley, S., Podoplanin-rich stromal networks induce dendritic cell motility via activation of CLEC-2. J. Immunol., 186, 2011, 102.21.
76. Prins, R.M., Craft, N., Bruhn, K.W., Khan-Farooqi, H., Koya, R.C., Stripecke, R., et al. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J. Immunol. 176 (2006), 157–164.
77. Quillien, V., Moisan, A., Carsin, A., Lesimple, T., Lefeuvre, C., Adamski, H., et al. Biodistribution of radiolabelled human dendritic cells injected by various routes. Eur. J. Nucl. Med. Mol. Imaging 32 (2005), 731–741.
78. Rambukkana, A., Pistoor, F., Bos, J.D., Kapsenberg, M.L., Das, P.K., Effects of contact allergens on human Langerhans cells in skin organ culture: migration, modulation of cell surface molecules, and early expression of interleukin-1 beta protein. Lab. Investig. J. Tech. Methods Pathol. 74 (1996), 422–436.
79. Rathinasamy, A., Czeloth, N., Pabst, O., Förster, R., Bernhardt, G., The origin and maturity of dendritic cells determine the pattern of sphingosine 1-phosphate receptors expressed and required for efficient migration. J. Immunol. 185 (2010), 4072–4081.
80. Ricart, B.G., John, B., Lee, D., Hunter, C.A., Hammer, D.A., Dendritic cells distinguish individual chemokine signals through CCR7 and CXCR4. J. Immunol. 186 (2011), 53–61.
81. Rizzo, M., Bayo, J., Piccioni, F., Malvicini, M., Fiore, E., Peixoto, E., et al. Low molecular weight hyaluronan-pulsed human dendritic cells showed increased migration capacity and induced resistance to tumor chemoattraction. PLoS One, 9, 2014, e107944.
82. Roake, J.A., Rao, A.S., Morris, P.J., Larsen, C.P., Hankins, D.F., Austyn, J.M., Dendritic cell loss from nonlymphoid tissues after systemic administration of lipopolysaccharide, tumor necrosis factor, and interleukin 1. J. Exp. Med. 181 (1995), 2237–2247.
83. Saalbach, A., Janik, T., Busch, M., Herbert, D., Anderegg, U., Simon, J., Fibroblasts support migration of monocyte‐derived dendritic cells by secretion of PGE2 and MMP-1. Exp. Dermatol., 2015.
84. Sabado, R.L., Bhardwaj, N., Cancer immunotherapy: dendritic-cell vaccines on the move. Nature 519 (2015), 300–301.
85. Scandella, E., Men, Y., Gillessen, S., Förster, R., Groettrup, M., Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood 100 (2002), 1354–1361.
86. Schumann, K., Lämmermann, T., Bruckner, M., Legler, D.F., Polleux, J., Spatz, J.P., et al. Immobilized chemokine fields and soluble chemokine gradients cooperatively shape migration patterns of dendritic cells. Immunity 32 (2010), 703–713.
87. Seton-Rogers, S., Immunotherapy: primed for a response. Nat. Rev. Cancer 15 (2015), 258–259.
88. Shalapour, S., Font-Burgada, J., Di Caro, G., Zhong, Z., Sanchez-Lopez, E., Dhar, D., et al. Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. Nature 521 (2015), 94–98.
89. Sixt, M., Interstitial locomotion of leukocytes. Immunol. Lett. 138 (2011), 32–34.
90. Soudja, S.M., Henri, S., Mello, M., Chasson, L., Mas, A., Wehbe, M., et al. Disrupted lymph node and splenic stroma in mice with induced inflammatory melanomas is associated with impaired recruitment of T and dendritic cells. PLoS One, 6, 2011, e22639.
91. Stoitzner, P., Zanella, M., Ortner, U., Lukas, M., Tagwerker, A., Janke, K., et al. Migration of langerhans cells and dermal dendritic cells in skin organ cultures: augmentation by TNF-alpha and IL-1beta. J. Leukoc. Biol. 66 (1999), 462–470.
92. Stoler-Barak, L., Moussion, C., Shezen, E., Hatzav, M., Sixt, M., Alon, R., Blood vessels pattern heparan sulfate gradients between their apical and basolateral aspects. PLoS One, 9, 2014, e85699.
93. Stripecke, R., del Carmen Villacres, M., Skelton, D., Satake, N., Halene, S., Kohn, D., Immune response to green fluorescent protein: implications for gene therapy. Gene Ther. 130 (1999), 5–12.
94. Stutte, S., Quast, T., Gerbitzki, N., Savinko, T., Novak, N., Reifenberger, J., et al. Requirement of CCL17 for CCR7- and CXCR4-dependent migration of cutaneous dendritic cells. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 8736–8741.
95. Subklewe, M., Geiger, C., Lichtenegger, F.S., Javorovic, M., Kvalheim, G., Schendel, D.J., et al. New generation dendritic cell vaccine for immunotherapy of acute myeloid leukemia. Cancer Immunol. Immunother. 63 (2014), 1093–1103.
96. Takamatsu, H., Takegahara, N., Nakagawa, Y., Tomura, M., Taniguchi, M., Friedel, R.H., et al. Semaphorins guide the entry of dendritic cells into the lymphatics by activating myosin II. Nat. Immunol. 11 (2010), 594–600.
97. Tal, O., Lim, H.Y., Gurevich, I., Milo, I., Shipony, Z., Ng, L.G., et al. DC mobilization from the skin requires docking to immobilized CCL21 on lymphatic endothelium and intralymphatic crawling. J. Exp. Med. 208 (2011), 2141–2153.
98. Teijeira, Á., Garasa, S., Peláez, R., Azpilikueta, A., Ochoa, C., Marré, D., et al. Lymphatic endothelium forms integrin-engaging 3D structures during DC transit across inflamed lymphatic vessels. J. Invest. Dermatol. 133 (2013), 2276–2285.
99. Teijeira, A., Russo, E., Halin, C., Taking the lymphatic route: dendritic cell migration to draining lymph nodes. Semin. Immunopathol. 36 (2014), 261–274.
100. Tomura, M., Hata, A., Matsuoka, S., Shand, F.H., Nakanishi, Y., Ikebuchi, R., et al. Tracking and quantification of dendritic cell migration and antigen trafficking between the skin and lymph nodes. Sci. Rep., 4, 2014.
101. Torzicky, M., Viznerova, P., Richter, S., Strobl, H., Scheinecker, C., Foedinger, D., et al. Platelet endothelial cell adhesion molecule-1 (PECAM-1/CD31) and CD99 are critical in lymphatic transmigration of human dendritic cells. J. Invest. Dermatol. 132 (2012), 1149–1157.
102. Tripp, C.H., Ebner, S., Ratzinger, G., Romani, N., Stoitzner, P., Conditioning of the injection site with CpG enhances the migration of adoptively transferred dendritic cells and endogenous CD8+ T-cell responses. J. Immunother. 33 (2010), 115–125.
103. Vandermeulen, G., Staes, E., Vanderhaeghen, M.L., Bureau, M.F., Scherman, D., Préat, V., Optimisation of intradermal DNA electrotransfer for immunisation. J. Control. Release 124 (2007), 81–87.
104. Verdijk, P., Aarntzen, E.H., Lesterhuis, W.J., Boullart, A.I., Kok, E., van Rossum, M.M., et al. Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin. Cancer Res. 15 (2009), 2531–2540.
105. Vigl, B., Aebischer, D., Nitschké, M., Iolyeva, M., Röthlin, T., Antsiferova, O., et al. Tissue inflammation modulates gene expression of lymphatic endothelial cells and dendritic cell migration in a stimulus-dependent manner. Blood 118 (2011), 205–215.
106. Villablanca, E.J., Mora, J.R., A two-step model for Langerhans cell migration to skin-draining LN. Eur. J. Immunol. 38 (2008), 2975–2980.
107. Villablanca, E.J., Raccosta, L., Zhou, D., Fontana, R., Maggioni, D., Negro, A., et al. Tumor-mediated liver X receptor-alpha activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses. Nat. Med. 16 (2010), 98–105.
108. Weber, M., Hauschild, R., Schwarz, J., Moussion, C., de Vries, I., Legler, D.F., et al. Interstitial dendritic cell guidance by haptotactic chemokine gradients. Science 339 (2013), 328–332.
109. Wong, J.L., Muthuswamy, R., Bartlett, D.L., Kalinski, P., IL-18-based combinatorial adjuvants promote the intranodal production of CCL19 by NK cells and dendritic cells of cancer patients. Oncoimmunology, 2, 2013, e26245.
110. Yaqub, S., Aandahl, E.M., Inflammation versus adaptive immunity in cancer pathogenesis. Crit. Rev.™ Oncog., 15, 2009.
111. Yin, X., Johns, S.C., Kim, D., Mikulski, Z., Salanga, C.L., Handel, T.M., et al. Lymphatic specific disruption in the fine structure of heparan sulfate inhibits dendritic cell traffic and functional T cell responses in the lymph node. J. Immunol. 192 (2014), 2133–2142.
112. Yu, H., Pardoll, D., Jove, R., STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 9 (2009), 798–809.
113. Zamarron, B.F., Chen, W., Dual roles of immune cells and their factors in cancer development and progression. Int. J. Biol. Sci. 7 (2011), 651–658.
114. Zhang, S.-N., Choi, I.-K., Huang, J.-H., Yoo, J.-Y., Choi, K.-J., Yun, C.-O., Optimizing DC vaccination by combination with oncolytic adenovirus coexpressing IL-12 and GM-CSF. Mol. Ther. 19 (2011), 1558–1568.
115. de Chickera, S., Willert, C., Mallet, C., Foley, R., Foster, P., Dekaban, G.A., Cellular MRI as a suitable, sensitive non-invasive modality for correlating in vivo migratory efficiencies of different dendritic cell populations with subsequent immunological outcomes. Int. Immunol., 2011, 2016, dxr095.
116. de Vries, I.J.M., Lesterhuis, W.J., Barentsz, J.O., Verdijk, P., van Krieken, J.H., Boerman, O.C., et al. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat. Biotechnol. 23 (2005), 1407–1413.